ThromboGenics to Host R&D Investor Meeting on Novel Disease-Modifying Approaches for Diabetic Eye Disease in London Today

18 Mar 2016

Leuven, 18 March 2016 – ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative treatments for back of the eye disease, will host an “R&D Investor Meeting” in London today focused on diabetic eye disease.

The meeting, which will be webcast live and accessible through ThromboGenic’s website, will feature clinical insights and expert views on diabetic eye disease, current treatments and key areas of unmet medical needs, provided by international experts: 

  • Prof Dr Reinier Schlingemann, Principal Investigator at theMedical Retina Unit and Ocular Angiogenesis Group, Department Of Ophthalmology at the AMC in Amsterdam, The Netherlands, and
  • Prof Dr Alan Stitt, Centre Director of the Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences at Queen's University Belfast, Ireland.

ThromboGenics CEO, Dr Patrik De Haes and senior members of ThromboGenics’ managementteamwill provide an update of the Company’s strategy and its diabetic eye disease drug development portfolio, which is built around four novel disease modifying programs.

Prof Dr Reinier Schlingemann, commenting on his presentation today said, “Diabetic retinopathy is a complex disease which progresses through a number of stages each of which requires its own specific treatment approach. There is a clear need for improved treatment options for patients with diabetic  eye disease, both proliferative diabetic retinopathy and diabetic macular edema, and I look forward to providing today’s audience with some insights into the most promising approaches to treating these significant sight threatening conditions.”

Prof Dr Alan Stitt, added, “Our greater understanding of the underlying causes of diabetic eye disease has led to the development of a number of pre-clinical models that provide the ability to generate new approaches to treating diabetic retinopathy and diabetic edema by acting on a number of novel targets. In my presentation I will outline the disease insights that these pre-clinical models have provided and how they are key tools in generating the new disease modifying drugs for the treatment of diabetic eye disease.”

Dr Patrik De Haes, CEO of ThromboGenics, commenting on today’s announcement, “Today is an important milestone for ThromboGenics as this IR event will allow us for the first time to update investors on the significant progress we have made in building an exciting drug development pipeline focused on diabetic eye disease. We believe that this novel pipeline will allow us to address a number of the most pressing unmet medical needs patients with diabetic eye disease encounter and to create important value for shareholders.”

Today’s event will take place from 14:00 to 16:30 GMT at the offices of Citigate Dewe Rogerson’s offices, 3 London Wall Buildings , London EC2M 5SY.  The meeting will not contain any price sensitive information.

To reserve a place, please email thrombogenics@citigatedr.co.uk .